After a 34-year-old woman suffered a stroke in Kansas, doctors there arranged for her to be transferred to a Boston hospital, via an Angel MedFlight Learjet. The woman and her father believed the cost of the medical flight would be covered by her private insurance. Then they got the bill.
Ski buff Sarah Witter will get $6,358.26 back from her hospital and insurer after a careful review of her bill following the KHN-NPR story on her case.
Washing poultry or meat before cooking it can do more harm than good — spreading pathogens that can be killed only in the cooking process. But the practice persists. Here’s what you need to know this holiday season.
A crowdsourced investigation in which we dissect, investigate and explain medical bills you send us.
The fallout continues from that Texas court decision that ruled Congress’ 2017 elimination of the tax penalty for failing to have insurance rendered the entire Affordable Care Act unconstitutional. Meanwhile, enrollment for 2019 at healthcare.gov was down, but far less than many predicted. KHN’s Julie Rovner, along with panelists Joanne Kenen of Politico, Anna Edney of Bloomberg News and Kimberly Leonard of the Washington Examiner, discuss this, plus the best, most overhyped and nerdiest stories of 2018. Also, Rovner interviews GOP strategist and pollster Frank Luntz.
Court watchers weren’t shocked when Reed O’Connor, a U.S. district judge in Texas, ruled the Affordable Care Act invalid. Critics say he usually sides with Republicans on ideological cases.
Many women aging alone want to hold on to their independence. But, when illness or disability strikes, they often need assistance. A program in New York, Philadelphia and San Francisco offers numerous ways to help.
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
As the number of people who inject drugs has soared, the rate of hepatitis C infection has climbed steeply, too, because the disease can be tied to sharing needles. Yet many drug patients are not checked for the virus that can damage the liver.
